Actively Recruiting
Evaluating Neoadjuvant Amivantamab With Lazertinib or Chemotherapy for Resectable EGFR-Mutated Non-Small Cell Lung Cancer
Led by Janssen Research & Development, LLC · Updated on 2026-11-03
68
Participants Needed
27
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the ability of a combination of amivantamab with either lazertinib or chemotherapy carboplatin and pemetrexed to slow down or stop the growth of resectable, epidermal growth factor receptor EGFR mutated, Stage II-IIIB non-small cell lung cancer NSCLC. NSCLC is the most common type of lung cancer and can occur due to mutations in various genes including EGFR. This Phase 2 trial focuses on treatment before surgery to improve outcomes in patients with this specific type and stage of lung cancer. Participants are assigned to one of two treatment groups one receiving amivantamab combined with lazertinib, and the other receiving amivantamab combined with carboplatin and pemetrexed chemotherapy. These treatments are given before surgery to remove the lung cancer. The study evaluates the safety and effects of these combinations in participants who have confirmed resectable NSCLC with specific EGFR mutations. During the study, participants undergo various assessments including biopsies if needed, and monitoring for treatment response and side effects. Researchers will measure outcomes such as major pathologic response, complete response after treatment, nodal downstaging at surgery, disease control rate, and adverse events. The study involves follow-up visits up to 1 year and 8 months to evaluate these outcomes and monitor participant safety throughout.
CONDITIONS
Brief Title
A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
Research Team
S
Study Contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here